BR100 Increased By (0.44%)
BR30 Increased By (1.39%)
KSE100 Increased By (0.62%)
KSE30 Increased By (0.61%)
BECO 5.49 No Change ▼ 0.00 (0%)
BML 56.00 Decreased By ▼ -0.76 (-1.34%)
BOP 35.41 Increased By ▲ 0.29 (0.83%)
CNERGY 8.20 Increased By ▲ 0.05 (0.61%)
DCL 11.55 Increased By ▲ 0.04 (0.35%)
FCCL 58.15 Increased By ▲ 1.40 (2.47%)
FCSC 5.15 No Change ▼ 0.00 (0%)
FFL 17.90 Increased By ▲ 0.02 (0.11%)
FNEL 1.25 No Change ▼ 0.00 (0%)
HUMNL 11.10 Decreased By ▼ -0.02 (-0.18%)
KEL 8.56 Increased By ▲ 0.14 (1.66%)
KOSM 6.75 Increased By ▲ 0.17 (2.58%)
MLCF 105.65 Increased By ▲ 2.35 (2.27%)
NBP 202.10 Increased By ▲ 1.92 (0.96%)
PACE 11.28 Decreased By ▼ -0.01 (-0.09%)
PAEL 44.42 Increased By ▲ 0.95 (2.19%)
PIAHCLA 28.66 Increased By ▲ 1.17 (4.26%)
PIBTL 18.75 Increased By ▲ 1.05 (5.93%)
PPL 248.10 Increased By ▲ 3.78 (1.55%)
PRL 35.35 Decreased By ▼ -0.08 (-0.23%)
PTC 66.15 Increased By ▲ 0.80 (1.22%)
SEARL 94.95 Increased By ▲ 1.63 (1.75%)
SSGC 32.04 Decreased By ▼ -0.90 (-2.73%)
TELE 8.93 Increased By ▲ 0.02 (0.22%)
THCCL 66.65 Decreased By ▼ -0.07 (-0.1%)
TPLP 10.76 Decreased By ▼ -0.07 (-0.65%)
TREET 25.22 Increased By ▲ 0.10 (0.4%)
TRG 64.21 Decreased By ▼ -0.69 (-1.06%)
WAVES 10.85 Decreased By ▼ -0.08 (-0.73%)
WTL 1.27 Increased By ▲ 0.02 (1.6%)
Business & Finance

McKinsey reaches $573mn settlement with US states over role in opioid crisis

  • Most money from the settlement with 47 states, the District of Columbia and five territories will go toward opioid treatment and prevention.
  • McKinsey did not admit liability or wrongdoing, and said it had also settled with two additional states, boosting its payout to nearly $600 million.
Published February 4, 2021 Updated February 4, 2021 08:51pm
By

McKinsey & Co, the consulting firm, has agreed to pay $573 million to resolve investigations by most US states over its alleged role in "turbocharging" sales of opioids such as OxyContin, fueling a nationwide epidemic.

Most money from the settlement with 47 states, the District of Columbia and five territories will go toward opioid treatment and prevention.

McKinsey did not admit liability or wrongdoing, and said it had also settled with two additional states, boosting its payout to nearly $600 million.

The firm must also turn over tens of thousands of internal documents concerning its work for drugmakers including Purdue Pharma, which is owned by the wealthy Sackler family and is the drugmaker most closely associated with the epidemic.

"They were part of a machine that disrupted, in fact destroyed, lives and families in America," California Attorney General Xavier Becerra said at a press conference. "Today we hold McKinsey to account."

McKinsey will continue investigating whether employees, including two partners, tried to destroy documents in response to probes concerning its work with Purdue.

"We deeply regret that we did not adequately acknowledge the tragic consequences of the epidemic," McKinsey Global Managing Partner Kevin Sneader said in a statement. "We hope to be part of the solution to the opioid crisis in the US"

In October, Purdue agreed to plead guilty to criminal charges over its marketing of OxyContin, as part of a more than $8 billion settlement.

Much of that sum will go unpaid, as states and other creditors try to recoup what they can in Purdue's bankruptcy proceedings, which began in 2019.

More than 3,300 lawsuits seek to hold drugmakers, distributors and pharmacies responsible for an opioid epidemic that led to an estimated 450,000 overdose deaths in the United States from 1999 to 2018.

"This crisis is fundamentally one of overprescribing," North Carolina Attorney General Josh Stein said at the press conference.

Comments

Comments are closed for this article.